<DOC>
	<DOCNO>NCT02234141</DOCNO>
	<brief_summary>This study compare efficacy , safety , tolerability three dos selonsertib ( GS-4997 ) placebo adult pulmonary arterial hypertension ( PAH ) . The study consist 24-week placebo-controlled treatment period long-term selonsertib treatment period . Participants complete 24-week placebo-controlled period eligible receive active treatment selonsertib long-term treatment period .</brief_summary>
	<brief_title>Selonsertib Adults With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Key Diagnosis idiopathic pulmonary arterial hypertension ( IPAH ) , heritable pulmonary arterial hypertension ( HPAH ) , drug toxininduced PAH , PAH associate connective tissue disease , HIV infection , congenital heart defect ( repair great 1 year prior Screening ) Meet follow hemodynamic criterion mean screen right heart catheterization ( RHC ) complete prior randomization : Mean pulmonary artery pressure ( mPAP ) ≥ 25 mm Hg Pulmonary vascular resistance ( PVR ) ≥ 400 dyne•sec/cm^5 Pulmonary capillary wedge pressure ( PCWP ) leave ventricular end diastolic pressure ( LVEDP ) ≤ 12 mm Hg PVR ≥ 400 &lt; 500 dynes•sec/cm^5 , PCWP/LVEDP ≤ 15 mm Hg PVR ≥ 500 dynes•sec/cm^5 Be able walk distance least 100 Have World Health Organization ( WHO ) Functional Class II III symptom Meet follow criterion determine pulmonary function test complete 24 week prior screen , perform without bronchodilation : Forced expiratory volume one second ( FEV1 ) ≥ 55 % predict normal FEV1 : force vital capacity ( FVC ) ratio ≥ 0.60 Receiving treatment one drug approve PAH ≥ 12 consecutive week stable dose ≥ 8 consecutive week Key Diagnosis PAH associate significant venous capillary involvement ( PCWP &gt; 15 mm Hg ) , pulmonary capillary hemangiomatosis , portal hypertension , unrepaired congenital heart defect Pulmonary hypertension ( PH ) belong group 2 5 2013 NICE classification Left ventricular ejection fraction ( LVEF ) ≤ 40 % clinically significant ischemic , valvular constrictive heart disease Uncontrolled hypertension ( ≥ 180/110 mm Hg ) Screening End stage renal disease ( receive peritoneal dialysis , hemodialysis , status renal transplantation ) Severe liver disease ( ChildPugh Class C , without cirrhosis ) Individuals may rescreened one additional time prior notification approval sponsor . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>